Roche Holding Tops List of Switzerland's Most Honored Companies in Institutional Investor's All-Europe Executive Team Ranking
25 mars 2014 03h00 HE
|
Institutional Investor
NEW YORK, NY--(Marketwired - Mar 25, 2014) - Roche Holding's CEO Severin Schwan claims victory as one of the Pharmaceuticals sector's best executives in the 2014 All-Europe Executive Team,...
Key Pharmaceutical Executive Joins Mesoblast
10 mars 2014 19h48 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, March 10, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Jonathan R. Symonds, CBE, the former...
Documents Uncovered by Judicial Watch Detail Big Pharma Campaign Access to Democratic Governors During 2012 National Governors Association Meeting
28 mars 2012 14h11 HE
|
Judicial Watch
WASHINGTON, DC--(Marketwire - Mar 28, 2012) - Judicial Watch, the public interest group that investigates and prosecutes government corruption, announced today that it has uncovered documents...
Invivoscribe Announces Collaboration Agreement to Develop Companion Diagnostic Test
15 févr. 2011 16h00 HE
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwire - February 15, 2011) - Invivoscribe™ Technologies, Inc., a world leader in personalized molecular medicine, announced today that they have entered into a...
MIT Enterprise Forum of Cambridge Presents "Vaccines and Global Health: New Technologies Create Global Opportunities"
04 nov. 2009 15h40 HE
|
MIT Enterprise Forum of Cambridge
CAMBRIDGE, MA--(Marketwire - November 4, 2009) - On November 9, the MIT Enterprise Forum of
Cambridge will present a session on the development of new technologies
for the research, development and...
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
09 mars 2009 07h00 HE
|
Human Genome Sciences, Inc.
ROCKVILLE, MD--(Marketwire - March 9, 2009) -
-- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met
the primary efficacy endpoint of sustained virologic response comparable...